Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Number of holders
-
19
-
Total 13F principal, excl. options
-
76.6M
-
Principal change
-
-6.35M
-
Total reported value, excl. options
-
$75.6M
-
Value change
-
-$18.7M
-
Number of buys
-
7
-
Number of sells
-
-10
-
Price
-
$0.97
Significant Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q2 2022
25 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q2 2022.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 19 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $76.6M of principal
.
Largest 10 bondholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ($57.8M of principal), OAKTREE CAPITAL MANAGEMENT LP ($6.97M of principal), MORGAN STANLEY ($4.2M of principal), Kohlberg Kravis Roberts & Co. L.P. ($3.16M of principal), Russell Investments Group, Ltd. ($1.59M of principal), L & S Advisors Inc ($795K of principal), STATE STREET CORP ($521K of principal), Jefferies Group LLC ($472K of principal), GAMCO INVESTORS, INC. ET AL ($250K of principal), and ZAZOVE ASSOCIATES LLC ($246K of principal).
This table shows the top 19 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.